Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study

Historically, the majority of patients with complement-mediated atypical hemolytic uremic syndrome (CaHUS) progress to end-stage kidney disease (ESKD). Single-arm trials of eculizumab with a short follow-up suggested efficacy. We prove, for the first time to our knowledge, in a genotype matched CaHU...

Descripción completa

Detalles Bibliográficos
Autores principales: Brocklebank, Vicky, Walsh, Patrick R., Smith-Jackson, Kate, Hallam, Thomas M., Marchbank, Kevin J., Wilson, Valerie, Bigirumurame, Theophile, Dutt, Tina, Montgomery, Emma K., Malina, Michal, Wong, Edwin K. S., Johnson, Sally, Sheerin, Neil S., Kavanagh, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Thrombosis and Hemostasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651868/
https://www.ncbi.nlm.nih.gov/pubmed/37369098
http://dx.doi.org/10.1182/blood.2022018833

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651868/
https://www.ncbi.nlm.nih.gov/pubmed/37369098
http://dx.doi.org/10.1182/blood.2022018833

Ejemplares similares